SOURCE: The Bedford Report

The Bedford Report

May 26, 2011 08:16 ET

Biotech Acquisition Speculation Heats Up

The Bedford Report Provides Analyst Research on Zalicus & Somaxon Pharmaceuticals

NEW YORK, NY--(Marketwire - May 26, 2011) - Recent studies have shown that the chances of FDA approval for early stage drugs is dropping significantly. Although it remains an exciting time in the biotech sector with several potential blockbusters working their way through the regulatory process, now, more than ever, many analysts are urging investors to use caution. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Zalicus, Inc. (NASDAQ: ZLCS) and Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX). Access to the full company reports can be found at:

www.bedfordreport.com/2011-05-ZLCS
www.bedfordreport.com/2011-05-SOMX

A study released by BIO and BioMedTracker claims that the success rate in bringing new medicines to market in the past six years is only about half of what it had been previously. The study claims, however that biotech drugs are twice as likely to gain approval, compared to more traditional chemical drugs.

The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Larger firms are leaning on acquisitions to quickly expand their product lines while smaller ones are opting for increased spending on research and development. This creates two potential avenues of profit for speculative biotech investors: a greater chance of a blockbuster drug or being acquired by a larger firm eager to boost its pipeline.

The Bedford Report releases regular market updates on the Healthcare Sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.bedfordreport.com and get exclusive access to our numerous analyst reports and industry newsletters.

Zalicus is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases. Mark H.N. Corrigan, MD, President and CEO of Zalicus said in a statement that the company plans to "initiate a Phase 2b clinical trial of Synavive for rheumatoid arthritis in the second quarter, and we identified promising Ion channel leads to move into clinical development for pain in the second half of the year."

Earlier this year Somaxon received a new patent on its insomnia drug Silenor, extending its exclusivity on the drug. The patents protecting the drug start to expire between March 2013 and February 2020.

The Bedford Report provides Analyst Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.bedfordreport.com/disclaimer

Contact Information